双参数与多参数前列腺MRI的阴性预测值:比较系统性综述与Meta分析
该系统综述与Meta分析纳入18项研究,比较双参数MRI(bpMRI)与多参数MRI(mpMRI)对临床显著前列腺癌(ISUP分级组≥2)的阴性预测值(NPV)。汇总NPV在bpMRI组(2857例)与mpMRI组(2751例)间无显著差异(92% vs 92%,p=.90),各亚组分析结果一致。结论提示bpMRI与mpMRI的NPV无显著差异,为bpMRI作为mpMRI的替代方案提供了进一步支持。
要点
- bpMRI与mpMRI对临床显著前列腺癌的汇总NPV无显著差异(92% vs 92%,p=.90)。
- 在排除高偏倚风险研究、1.5-T、3-T、活检初治及既往活检亚组中,NPV均无显著差异。
- 多数研究为模拟bpMRI(按mpMRI扫描但解读时去除动态对比增强图像),仅3项为平行组比较。
核心结论
- 本研究未发现bpMRI与mpMRI在临床显著前列腺癌NPV方面存在显著差异的证据。
研究设计与样本
- 比较系统性综述与Meta分析,检索多个文献数据库、试验注册库和会议论文集,纳入18项报告bpMRI与mpMRI比较结果的研究,参考标准为病理(活检和/或根治性前列腺切除术),采用QUADAS-Comparative评估偏倚风险,随机效应Meta分析计算汇总NPV。
诊断标准与关键数值
- 阴性检查定义为PI-RADS分类或Likert评分1或2分;临床显著前列腺癌定义为ISUP分级组≥2;汇总NPV在bpMRI组(n=2857)为92%(95%CI 89-94%),mpMRI组(n=2751)为92%(95%CI 89-94%),p=.90。
临床应用与阅片要点
- 作者结论认为结果进一步支持bpMRI作为mpMRI在临床实践中的替代方案;未来研究应包括随机设计和纵向随访。
局限性
- 15项研究评估的是模拟bpMRI检查(按mpMRI执行但解读时去除动态对比增强图像)。
- 仅3项研究比较了接受bpMRI或mpMRI的平行组患者。
- 无研究评估随机分配接受bpMRI或mpMRI的患者。
- 3项研究的参考标准包括纵向随访活检。
- 未来研究应包括随机设计和纵向随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Evidence supports comparable PPV between biparametric MRI (bpMRI) and multiparametric MRI (mpMRI). However, concern regarding missed cancers limits wider adoption of bpMRI. OBJECTIVE. The purpose of this study was to compare bpMRI and mpMRI in terms of the NPV for clinically significant prostate cancer. EVIDENCE ACQUISITION. Multiple publication databases, trial registries, and conference proceedings were searched over varying time frames to identify studies reporting comparative results for bpMRI and mpMRI. Information was extracted for negative examinations (PI-RADS category or Likert scale score of 1 or 2), which were classified as true- or false-negative for clinically significant prostate cancer (International Society of Urological Pathology [ISUP] grade group ≥ 2), with a pathologic reference standard (biopsy and/or radical prostatectomy). Risk of bias was assessed using QUADAS-Comparative. Pooled NPVs were calculated using random-effects meta-analysis. EVIDENCE SYNTHESIS. The meta-analysis included 18 studies. Fifteen studies evaluated simulated bpMRI examinations (examinations performed as mpMRI but interpreted with the removal of dynamic contrast-enhancement images); three studies compared parallel arms of patients who underwent bpMRI or mpMRI. No study evaluated patients randomly allocated to undergo bpMRI or mpMRI. The reference standard of three studies included longitudinal follow-up biopsy. Pooled NPV was not significantly different between bpMRI (n = 2857 patients) and mpMRI (n = 2751 patients) overall (92% [95% CI, 89-94%] vs 92% [95% CI, 89-94%]; p = .90) in nine studies after exclusion of studies with a high risk of bias in at least one domain of QUADAS-Comparative (92% [95% CI, 86-95%] vs 92% [95% CI, 95-96%]; p = .83), in three studies of 1.5-T examinations only (89% [95% CI, 78-95%] vs 87% [95% CI, 77-93%]; p = .76), in 12 studies of 3-T examinations only (93% [95% CI, 90-95%] vs 93% [95% CI, 91-95%]; p = .90), in 12 studies of biopsy-naive patients only (92% [95% CI, 88-94%] vs 91% [95% CI, 89-93%]; p = .89), or in three studies of previously biopsied patients only (94% [95% CI, 89-97%] vs 94% [95% CI, 85-98%]; p = .95). CONCLUSION. This study found no evidence of a significant difference between bpMRI and mpMRI in terms of NPV for clinically significant prostate cancer. CLINICAL IMPACT. The results provide further support for bpMRI as an alternative to mpMRI in clinical practice. Future studies should include randomized designs with longitudinal follow-up. TRIAL REGISTRATION. PROSPERO identifier CRD42023491456.
引用
- Salinas-Miranda E, Birosh A, McInnes MDF, et al. NPV of Biparametric and Multiparametric Prostate MRI: A Comparative Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2025. PMID: 40042922. doi:10.2214/AJR.24.32328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。